PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21846498-4	2011	We targeted adenosine kinase (ADK), the key enzyme in adenosine metabolism, using a treatment regime with the selective ADK inhibitor ABT-702 (1.5mg/kg intraperitoneally twice a week) commencing at the age of three months or six months.	ABT 702	134-141	adenosine kinase	Mus musculus	12-28
23018889-7	2013	However, treatment with 8-Cl-cAMP and AICAR induced the phosphorylation of Akt/PKB, which was inhibited by ABT702 (an adenosine kinase inhibitor) and NBTI (an adenosine transporter inhibitor).	ABT 702	107-113	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	38-43
23018889-7	2013	However, treatment with 8-Cl-cAMP and AICAR induced the phosphorylation of Akt/PKB, which was inhibited by ABT702 (an adenosine kinase inhibitor) and NBTI (an adenosine transporter inhibitor).	ABT 702	107-113	AKT serine/threonine kinase 1	Homo sapiens	75-82
23232950-10	2013	The protective effects are also partially dependent on adenosine kinase, as the inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl (ABT 702, 30 microM) significantly reversed the protective effect of both adenosine and inosine during hypoxia and re-oxygenation.	ABT 702	176-183	adenosine kinase	Homo sapiens	55-71
21846498-4	2011	We targeted adenosine kinase (ADK), the key enzyme in adenosine metabolism, using a treatment regime with the selective ADK inhibitor ABT-702 (1.5mg/kg intraperitoneally twice a week) commencing at the age of three months or six months.	ABT 702	134-141	adenosine kinase	Mus musculus	30-33
21846498-4	2011	We targeted adenosine kinase (ADK), the key enzyme in adenosine metabolism, using a treatment regime with the selective ADK inhibitor ABT-702 (1.5mg/kg intraperitoneally twice a week) commencing at the age of three months or six months.	ABT 702	134-141	adenosine kinase	Mus musculus	120-123
16972264-4	2006	8-Cl-cAMP and 8-Cl-adenosine could increase Rap1 activity, which was blocked by ABT702-an adenosine kinase inhibitor.	ABT 702	80-86	RAS-related protein 1a	Mus musculus	44-48
21335462-6	2011	In support of a role for intracellular adenosine metabolism in regulating hypertrophy, the adenosine kinase (AK) inhibitors iodotubercidin and ABT-702 completely reversed the attenuation of cell size, protein synthesis, and expression of ANP by CADO or ADO.	ABT 702	143-150	adenosine kinase	Rattus norvegicus	91-107
21335462-6	2011	In support of a role for intracellular adenosine metabolism in regulating hypertrophy, the adenosine kinase (AK) inhibitors iodotubercidin and ABT-702 completely reversed the attenuation of cell size, protein synthesis, and expression of ANP by CADO or ADO.	ABT 702	143-150	adenosine kinase	Rattus norvegicus	109-111
34773542-10	2021	Moreover, the ADK inhibitor, ABT702, blocks SEW2871-induced hypersensitivity.	ABT 702	29-35	adenosine kinase	Rattus norvegicus	14-17
15476699-0	2004	The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats.	ABT 702	31-38	adenosine kinase	Rattus norvegicus	4-20
15476699-1	2004	ABT-702 is a novel and selective non-nucleoside adenosine kinase (AK) inhibitor that produces increases in endogenous extracellular adenosine.	ABT 702	0-7	adenosine kinase	Rattus norvegicus	48-64
11082453-0	2000	ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I.	ABT 702	0-7	adenosine kinase	Mus musculus	115-131
11082453-9	2000	Kinetic studies revealed that AK inhibition by ABT-702 was competitive with respect to ADO and noncompetitive with respect to MgATP(2-).	ABT 702	47-54	adenosine kinase	Mus musculus	30-32
11082453-10	2000	AK inhibition by ABT-702 was demonstrated to be reversible after 4 h of dialysis.	ABT 702	17-24	adenosine kinase	Mus musculus	0-2
11082453-19	2000	Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively reduces acute thermal nociception in the mouse by a nonopioid, non-nonsteroidal anti-inflammatory drug, ADO A(1) receptor-mediated mechanism.	ABT 702	6-13	adenosine kinase	Mus musculus	51-53
11082454-0	2000	ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties.	ABT 702	0-7	adenosine kinase	Rattus norvegicus	116-132
11082454-0	2000	ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties.	ABT 702	9-88	adenosine kinase	Rattus norvegicus	116-132
11082454-5	2000	The effects of ABT-702, a novel, potent (IC(50) = 1.7 nM), and selective non-nucleoside AK inhibitor were examined in rat models of nociception and acute inflammation.	ABT 702	15-22	adenosine kinase	Rattus norvegicus	88-90
11082454-15	2000	Thus, ABT-702 is a novel, non-nucleoside AK inhibitor, with a nonopioid, non-nonsteroidal anti-inflammatory drug mechanism of action, which shows antinociceptive and anti-inflammatory activity in vivo.	ABT 702	6-13	adenosine kinase	Rattus norvegicus	41-43
15476699-1	2004	ABT-702 is a novel and selective non-nucleoside adenosine kinase (AK) inhibitor that produces increases in endogenous extracellular adenosine.	ABT 702	0-7	adenosine kinase	Rattus norvegicus	66-68
11405650-0	2001	Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor.. Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation.	ABT 702	13-91	adenosine kinase	Homo sapiens	126-142
34773542-13	2021	In support of this idea, recombinant rat (rrIL-1beta)-induced allodynia was blocked by at least 90% with ABT702, functionally linking ADK to IL-1beta.	ABT 702	105-111	adenosine kinase	Rattus norvegicus	134-137
34773542-13	2021	In support of this idea, recombinant rat (rrIL-1beta)-induced allodynia was blocked by at least 90% with ABT702, functionally linking ADK to IL-1beta.	ABT 702	105-111	interleukin 1 alpha	Rattus norvegicus	141-149
34773542-14	2021	Moreover, the selective A3AR antagonist, MRS1523, prevents the ability of ABT702 to block SEW2871 and IL-1beta-induced allodynia, implicating A3AR signaling in the beneficial effects exerted by ABT702.	ABT 702	74-80	interleukin 1 alpha	Rattus norvegicus	102-110
31525084-8	2019	Isolated rat and human arterioles incubated with adenosine (10 nmol/L) or ADK inhibitor ABT-702 (0.1 micromol/L) both displayed augmented conducted vasodilation.	ABT 702	88-95	adenosine kinase	Homo sapiens	74-77
35618039-3	2022	We found that ABT-702 treatment significantly reduced cardiac ADK protein content in mice 24-72 h after administration (IP or oral).	ABT 702	14-21	adenosine kinase	Mus musculus	62-65
35618039-8	2022	Together, these results indicate that ABT-702 induces a distinct form of delayed cardioprotection mediated by adenosine receptor-dependent, proteasomal degradation of cardiac ADK and enhanced adenosine signaling in the late phase.	ABT 702	38-45	adenosine kinase	Mus musculus	175-178
35618039-0	2022	Adenosine kinase (ADK) inhibition with ABT-702 induces ADK protein degradation and a distinct form of sustained cardioprotection.	ABT 702	39-46	adenosine kinase	Mus musculus	0-16
35618039-0	2022	Adenosine kinase (ADK) inhibition with ABT-702 induces ADK protein degradation and a distinct form of sustained cardioprotection.	ABT 702	39-46	adenosine kinase	Mus musculus	18-21
35618039-0	2022	Adenosine kinase (ADK) inhibition with ABT-702 induces ADK protein degradation and a distinct form of sustained cardioprotection.	ABT 702	39-46	adenosine kinase	Mus musculus	55-58
35618039-2	2022	Here, we identified a novel, extended effect of the ADK inhibitor, ABT-702, on cardiac ADK protein longevity and investigated its impact on sustained adenosinergic cardioprotection.	ABT 702	67-74	adenosine kinase	Mus musculus	52-55
35618039-2	2022	Here, we identified a novel, extended effect of the ADK inhibitor, ABT-702, on cardiac ADK protein longevity and investigated its impact on sustained adenosinergic cardioprotection.	ABT 702	67-74	adenosine kinase	Mus musculus	87-90
32544464-5	2020	Our previous studies have shown that pretreatment of adenosine kinase inhibitor ABT-702 could markedly attenuate cisplatin-induced nephrotoxicity both in vivo and in vitro.	ABT 702	80-87	adenosine kinase	Homo sapiens	53-69
27022463-8	2015	5-(3-Bromophenyl)-7-[6-(4-morpholinyl)-3-pyrido[2,3-d]byrimidin-4-amine dihydrochloride (ABT-702), an adenosine kinase inhibitor (5 mg/kg, i.p.	ABT 702	89-96	adenosine kinase	Rattus norvegicus	102-118
30910669-8	2019	In neonatal cardiomyocytes exposed to hypertrophic stress, 2-chloroadenosine (CADO) or adenosine treatment suppressed MT detyrosination, which was reversed by ADK inhibition with iodotubercidin or ABT-702.	ABT 702	197-204	adenosine kinase	Mus musculus	159-162
30995110-6	2019	In the present study, pretreatment with the ADK inhibitor ABT-702 could markedly attenuate cisplatin-induced acute kidney injury, tubular cell apoptosis, oxidative stress, and inflammation in the kidneys.	ABT 702	58-65	adenosine kinase	Homo sapiens	44-47
24841126-5	2014	Control and diabetic mice were then treated with the adenosine kinase inhibitor ABT702 (1.5mg/kg, i.p.	ABT 702	80-86	adenosine kinase	Mus musculus	53-69
26066576-0	2015	An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat.	ABT 702	31-38	adenosine kinase	Rattus norvegicus	3-19
26066576-2	2015	ABT-702, a non-nucleoside AK inhibitor, shows analgesic effect in animal models of pain.	ABT 702	0-7	adenosine kinase	Rattus norvegicus	26-28
23770229-9	2013	The involvement of adenosine signaling in the anti-inflammation effect of ABT-702 was supported by the TNF-alpha release blocking effect of A2AAR antagonist in AGA-treated microglial cells.	ABT 702	74-81	tumor necrosis factor	Mus musculus	103-112
23770229-9	2013	The involvement of adenosine signaling in the anti-inflammation effect of ABT-702 was supported by the TNF-alpha release blocking effect of A2AAR antagonist in AGA-treated microglial cells.	ABT 702	74-81	adenosine A2a receptor	Mus musculus	140-145